share_log

Citigroup Upgrades Mersana Therapeutics to Buy, Raises Price Target to $5

Benzinga ·  Dec 4, 2023 11:16

Citigroup analyst Ashiq Mubarack upgrades Mersana Therapeutics (NASDAQ:MRSN) from Neutral to Buy and raises the price target from $1 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment